Patients and
Physicians
Clinical Studies
At Walden, we are committed to developing promising new therapies for people living with kidney disease. Patients are central to all we do, and our therapeutics and clinical studies are designed with that in mind. We invite you to learn more about our ongoing studies at clinicaltrials.gov.
 |
 |
 |
1The following indications are included: diabetic nephropathy (DN), primary focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), immunoglobulin A nephropathy (IgAN), and primary membranous nephropathy (PMN).
Expanded Access policy
We understand that there may be circumstances under which patients or caregivers may request treatment with our investigative therapies before they have been approved by regulatory agencies. This is sometimes called “expanded access,” “right to try,” “compassionate use,” “early access,” or a “named patient program.” We use the term “expanded access” to capture all of these.
In lieu of expanded access, Walden encourages patients to participate in clinical studies. Clinical studies ensure that the safety and efficacy of the investigational therapy are evaluated prior to submission for review and potential approval by regulatory authorities. Therefore, after careful consideration, Walden, as a clinical-stage company, has decided that the best way for patients to access our investigational therapies is through clinical study participation. As a result, we will not offer expanded access at this time.
Any requests for expanded access of our investigational products may be referred to study investigators to determine a patient’s eligibility for one of our ongoing clinical studies.
Once we have completed pivotal trials to more fully inform the potential benefits and risks of our products in development, we will evaluate the initiation of an expanded access program. Should changes be made to our expanded access policy, we will update this website.
Walden may revise this policy at any time as provided by the 21st Century Cures Act.
Patient Resources
American Association of Kidney Patients (AAKP)
AAKP is dedicated to improving the lives and long-term outcomes of kidney patients through education, advocacy, patient engagement, and the fostering of patient communities.
NephCure
NephCure’s mission is to empower people with rare, protein-spilling kidney disease to take charge of their health, while leading the revolution in research, new treatments, and care.
National Kidney Foundation (NKF)
The NKF is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation.
The International Society of Glomerular Disease (ISGD)
The ISGD brings together stakeholders from the clinic, academia, industry, patient advocacy groups, and professional societies to ensure all people can access accurate early diagnosis and suitable treatment to preserve the health of their kidneys.
IgA Nephropathy Foundation
The IgA Nephropathy Foundation’s mission is to be a patient-centric organization focused on finding a cure for IgAN. Using the power of the patient community, they are focused on funding research, using patient advocacy to empower patients, and building a network of support.